HANA BIOSCIENCES TO LICENSE THREE TARGETED CANCER DRUG CANDIDATES FROM INEX PHARMACEUTICALS

Hana Biosciences signed a letter of intent to license the worldwide rights to develop and commercialize three novel targeted chemotherapy drug candidates for the treatment of solid and hematological cancers from Inex Pharmaceuticals Corporation. The three candidates are known as Marqibo (sphingosomal vincristine), sphingosomal vinorelbine, and sphingosomal topotecan.

INS News (http://feed.insnews.org/v-cgi/feeds.cgi?feedid=150&story_id=1691043)